Jordan Axelrad, MD, MPH

Iron Deficiency Anemia in Gastroenterology: Managing Underlying Causes and Tackling Treatment Challenges 

This presentation on managing iron deficiency anemia (IDA) in gastroenterology discusses common causes, treatment options, and evolving therapies. It emphasizes the importance of understanding the underlying causes and selecting appropriate treatments for patients with IDA, particularly those with gastrointestinal conditions.

 In clinical practice, iron deficiency often results from malabsorption, chronic blood loss, and dietary issues. Identifying the root cause of the deficiency is crucial for effective management.

 Intravenous (IV) iron is beneficial for a wide range of patients, especially when oral iron is poorly tolerated, as in inflammatory bowel disease. Recent advancements have improved tolerance to IV iron, making it a viable option for many patients. Oral iron regimens, such as administering iron every other day, may be better tolerated for some individuals.

 It is important to differentiate between iron deficiency and anemia through proper screening, including ferritin and iron saturation tests. Gastrointestinal issues can complicate the use of oral iron.

Iron deficiency in gastric bypass patients:

 Patients who have undergone gastric bypass surgery are at higher risk for iron deficiency. These patients may require more tailored approaches, including IV iron therapy, depending on their specific needs.

 The safety profiles of different IV iron formulations vary. Misconceptions about IV iron, such as concerns about safety, need to be addressed. Clinicians should be familiar with the various formulations and their associated risks.

 Choosing the appropriate treatment for each patient depends on their individual condition and tolerance. Clinicians should understand what to expect from different therapies and when to make treatment adjustments.

 Adverse reactions to IV iron infusions, though rare, can occur. Physicians should be prepared to manage these reactions promptly if they arise.

 Ferric carboxymaltose is an emerging IV iron formulation that has shown lower adverse reactions in some cases. However, it carries a risk of hypophosphatemia, and phosphate levels should be monitored. This formulation may not be suitable for all patients.

 Experts from both hematology and gastroenterology provide final thoughts, offering pearls of wisdom for nonhematologists on managing IDA, highlighting the importance of personalized treatment strategies.

In summary, successful management of IDA requires a comprehensive understanding of the causes, treatment options, and individual patient needs. Regular monitoring and the careful selection of iron therapies, including IV options, are essential for optimal patient care.

Videos

Panelists discuss how understanding the causes of iron deficiency anemia, selecting appropriate treatments such as intravenous iron, and tailoring therapies to individual patient needs are critical for effective management, particularly in patients with gastrointestinal conditions.

Video: Iron Deficiency Anemia in Gastroenterology: Managing Underlying Causes and Tackling Treatment Challenges 

Iron deficiency in gastric bypass patients

Podcasts

The expert panel concludes its discussion with insights on how collaboration and communication across various healthcare specialties improve the care of patients treated for iron deficiency anemia.

Collaboration and Communication Across the Healthcare Team

Video content above is prompted by the following:

How does collaboration and communication amongst the interprofessional healthcare team enhance the delivery of care and improve outcomes for patients treated for iron deficiency anemia with iron dextran?

The panel discusses the mechanism of treatment-emergent hypophosphatemia that occurs following the administration of certain intravenous iron formulations.

Treatment-Emergent Hypophosphatemia Following Administration of Intravenous Iron

Treatment-emergent hypophosphatemia is now widely recognized as a phenomenon that can occur following administration of certain IV iron formulations and within the first 2 weeks after administration. Can you discuss the mechanism of treatment-emergent hypophosphatemia?

Jordan Axelrad, MD, MPH

Articles